The abstract is read at the publisher; the summary is JClub's.
Cullin-5 (CRL5) limits persistence and effector function of primary human CD8+ T cells during repeated NY-ESO-1-specific tumor rechallenge, with CRL5 disruption preserving cytotoxicity and cytokine output.
- Why it matters: Exhaustion undermines durable antitumor responses and constrains adoptive cell therapies in solid tumors, so regulators of T-cell persistence are needed.
- What they did: Genome-wide CRISPR knockout screens in primary human CD8+ T cells expressing an NY-ESO-1-specific T-cell receptor were tested under repeated tumor cell rechallenge, highlighting CRL5 components (CUL5, RNF7, ARIH2). CRL5 loss was modeled genetically and by pharmacologic cullin neddylation inhibition using MLN4924.
- The result: CRL5 disruption preserved effector-associated transcriptional programs, suppressed exhaustion-related signatures, and improved tumor control in a human melanoma xenograft after ACT with CRL5-deficient T cells.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.